Ludwigshafen, Germany

Franz Reicheneder

This inventor holds 4 USPTO granted patents. Top assignees: Basf Aktiengesellschaft, Badische Anilin- & Soda-Fabrik Aktiengesellschaft. Active years: 1976-1989.


% Patents Active = 100.0

Average Co-Inventor Count = 5.1

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 1976-1989

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Franz Reicheneder: Innovator in Pharmaceutical Chemistry

Introduction

Franz Reicheneder is a notable inventor based in Ludwigshafen, Germany. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative patents. With a total of 4 patents, Reicheneder has focused on developing compounds that have potential therapeutic applications.

Latest Patents

Among his latest patents, Reicheneder has developed novel pyridazinone-imines. These compounds are characterized by their unique formula and are substituted at the imine nitrogen. They are designed to be used as drugs, particularly as antidepressants, antiparkinson drugs, and antihypotonic agents. Additionally, he has worked on pyridazinium compounds, which serve as intermediates and are of interest due to their pharmacological properties.

Career Highlights

Reicheneder has had a distinguished career, working with prominent companies such as BASF and Badische Anilin- & Soda-Fabrik Aktiengesellschaft. His work in these organizations has allowed him to contribute to various innovative projects and advancements in pharmaceutical chemistry.

Collaborations

Throughout his career, Reicheneder has collaborated with notable individuals, including Rudolf Kropp and August Amann. These collaborations have further enriched his research and development efforts.

Conclusion

Franz Reicheneder's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the field, paving the way for new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…